Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems01:22

Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems

Bioavailability is a critical pharmacological concept that measures the extent and rate at which an active drug ingredient or therapeutic moiety enters the systemic circulation, remaining unchanged. It's a pivotal factor in determining a drug's efficacy and safety.The Biopharmaceutics Classification System (BCS) plays an essential role in drug development by categorizing drugs into four classes based on their solubility and permeability. This classification aids in understanding drug absorption...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Global changes in gene expression and splicing in alcoholic liver disease.

Scientific reports·2026
Same author

The role of proinflammatory response and the kynurenine pathway in the association between childhood maltreatment and lifetime substance use disorder.

Neurobiology of stress·2026
Same author

Evaluation of a novel eating disorder prevention programme (Australian diabetes body project) for young women with type 1 diabetes in a clinic setting: A randomized controlled trial protocol.

Diabetic medicine : a journal of the British Diabetic Association·2026
Same author

The neurobiological cravings signature (NCS) as a predictive neuromarker of clinical outcomes in alcohol use disorder.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·2026
Same author

Transcranial magnetic stimulation in cocaine use disorder and the risk of seizure: a review of the evidence.

Frontiers in psychiatry·2026
Same author

Functional neuroimaging of fatty acid amide hydrolase inhibition in posttraumatic stress disorder: a randomized clinical trial.

Translational psychiatry·2026
Same journal

Classifying Psychedelic-Related Complications.

Current topics in behavioral neurosciences·2026
Same journal

Psychedelic-Related Psychosis: From Model Psychosis to Psychotherapy.

Current topics in behavioral neurosciences·2026
Same journal

Managing Psychological Challenges in the Subacute ("Afterglow") Window of Psychedelic Drug Effects.

Current topics in behavioral neurosciences·2025
Same journal

Flashbacks, Hallucinogen Persisting Perception Disorder (HPPD), and Reactivations Following the Use of Classic Psychedelics: Classification and Therapeutic Management.

Current topics in behavioral neurosciences·2025
Same journal

Correction to: Psychedelic Drug Checking: Analytical and Strategic Challenges in Harm Reduction for Classic Psychedelics.

Current topics in behavioral neurosciences·2025
Same journal

Ontologically Challenging Psychedelic Experiences: Considerations for Managing Associated Distress.

Current topics in behavioral neurosciences·2025
See all related articles

Related Experiment Video

Updated: Jun 1, 2026

High-throughput Screening for Chemical Modulators of Post-transcriptionally Regulated Genes
09:44

High-throughput Screening for Chemical Modulators of Post-transcriptionally Regulated Genes

Published on: March 3, 2015

Translational approaches to medication development.

Selena Bartlett1, Markus Heilig

  • 1Preclinical Development Group, Ernest Gallo Clinic and Research Center, University of California San Francisco, 5858 Horton Street, Emeryville, CA 94608, USA. SelenaB@gallo.ucsf.edu

Current Topics in Behavioral Neurosciences
|May 19, 2011
PubMed
Summary
This summary is machine-generated.

Developing new alcoholism treatments is crucial as current options are insufficient. This research focuses on translational neuroscience to create novel pharmacotherapies targeting key brain receptors for addiction.

More Related Videos

Quantitative Immunofluorescence to Measure Global Localized Translation
09:13

Quantitative Immunofluorescence to Measure Global Localized Translation

Published on: August 22, 2017

Cost-Efficient Transcriptomic-Based Drug Screening
06:40

Cost-Efficient Transcriptomic-Based Drug Screening

Published on: February 23, 2024

Related Experiment Videos

Last Updated: Jun 1, 2026

High-throughput Screening for Chemical Modulators of Post-transcriptionally Regulated Genes
09:44

High-throughput Screening for Chemical Modulators of Post-transcriptionally Regulated Genes

Published on: March 3, 2015

Quantitative Immunofluorescence to Measure Global Localized Translation
09:13

Quantitative Immunofluorescence to Measure Global Localized Translation

Published on: August 22, 2017

Cost-Efficient Transcriptomic-Based Drug Screening
06:40

Cost-Efficient Transcriptomic-Based Drug Screening

Published on: February 23, 2024

Area of Science:

  • Addiction Neuroscience
  • Pharmacotherapy Development
  • Translational Research

Background:

  • Alcoholism is a leading cause of global disability, yet effective treatments remain limited.
  • Advances in addiction neuroscience have not translated into sufficient clinical treatment options.
  • Developing novel pharmacotherapies is essential to address the treatment gap in alcoholism.

Purpose of the Study:

  • To describe the experience of building translational research programs for novel alcoholism pharmacotherapies.
  • To discuss critical factors for translating basic addiction neuroscience into clinical treatments.
  • To explore the role of collaborations in advancing addiction treatment development.

Main Methods:

  • Focus on developing pharmacotherapies targeting specific neurobiological mechanisms.
  • Investigated four key receptor systems: cholinergic nicotine, corticotropin-releasing hormone (CRH), neurokinin 1 (NK1), and hypocretin/orexin.
  • Emphasized a translational research approach from basic science to clinical application.

Main Results:

  • Experience in building translational research programs for alcoholism pharmacotherapy.
  • Identified critical considerations for successful translation of neuroscience findings.
  • Highlighted the importance of academic and industry partnerships.

Conclusions:

  • Translational research is vital for developing new alcoholism treatments.
  • Targeting specific neurobiological pathways offers potential for novel pharmacotherapies.
  • Collaboration between diverse stakeholders is key to bringing treatments to patients.